Auro Vaccines Private Limited, a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has terminated the License Agreement (entered on September 27, 2023) with Hilleman Laboratories Singapore Pte, Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.

Auro Vaccines Private Limited is not a material subsidiary to the company and the termination of a Licence Agreement for a very early-stage vaccine asset is not a material event. This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials.